Edwin Ofori Atta: High-Dose Vitamin C and Vascular Function
Edwin Ofori Atta, Head Of Pharmacy at Kumasi Hospital, shared a post on LinkedIn:
“Taking 2 g of vitamin C reduces arterial stiffness by about 9.6 percent within 6 hours and reduces platelet aggregation by about 35%, which may help lower the risk of blood clots.
Specifically high-dose vitamin C reducing arterial stiffness and platelet aggregation within 6 hours, are supported by clinical studies on cardiovascular health.
Vitamin C functions as a powerful antioxidant, scavenging free radicals and improving the bioavailability of nitric oxide.
Increased nitric oxide bioavailability allows blood vessels to relax (vasodilation) and prevents platelets from sticking together.
Double-blind, randomized study found that acute oral administration of high-dose vitamin C significantly increased plasma levels, which reduced the augmentation index (a key measure of arterial stiffness) within 6 hours.
While this study was on healthy individuals, similar studies indicate that vitamin C provides significant cardiovascular benefits by protecting the endothelium (vessel lining) and reducing platelet activation, particularly in individuals with high oxidative stress.”
Stay updated with Hemostasis Today.
-
Apr 7, 2026, 15:32Brad McEwen: Dark Chocolate and Cardiometabolic Health
-
Apr 7, 2026, 14:50Sean O.: The Urgent Need for Blood in the United States
-
Apr 7, 2026, 14:42Samson Kraikue-Quaicoe: The Role of Minor Fractions in Advanced Medical Care Beyond Whole Blood and Primary Components
-
Apr 7, 2026, 14:36Heghine Khachatryan: When Bleeding Speaks – Think Beyond Gynecology
-
Apr 7, 2026, 13:50Annie Bauzon: How to Properly Make a Peripheral Blood Smear
-
Apr 7, 2026, 13:42Timothy Lesaca: How SSRIs Influence Hemostasis Through Platelets
-
Apr 7, 2026, 13:32Bastu Odoka: Storage Lesions – What Really Happens to Stored Blood
-
Apr 7, 2026, 13:15Mehmet Semin Çakir: Ticagrelor-Based Dual Antiplatelet Therapy in Stent Assisted Endovascular Treatment
-
Apr 6, 2026, 16:39Dhinesh Selvaraju: FDA Approves Narsoplimab (Yartemlea) as 1st Treatment for TA-TMA in Adults and Children